21. Popescu, F.D., 2003 - Antihistaminicele în alergologie. Editura Universitară “Carol Davila”, Bucureşti, 31-58. 22. Popescu, F.D., Iancău, M., Popescu, F., Georgescu, M., 2003 - Loratadine safety pr<strong>of</strong>ile on central nervous system, Conferinţa Anuală a Societăţii Române <strong>de</strong> Alergologie şi Imunologie Clinică, Cluj-Napoca, Volum rezumate, 54, 140. 23. Ramaekers, J.G., Uiterwijk, M.M.C., O'Hanlon, J.F., 1992 - Effects <strong>of</strong> loratadine and cetirizine on actual driving performance and psychometric test performance, and EEG during driving. Eur. J. Clin. Pharmacol., 42, 363-369. 24. Ramaekers, J.G., Vermeeren, A., 2000 - All antihistamines cross blood-brain, B.M.J., 321, 572. 25. Ridout, F., Shamsi, Z., Meadows, R., Johnson, S., Hindmarch, I., 2003 - A single-center, randomized, double-blind, placebo-controlled, crossover investigation <strong>of</strong> the effects <strong>of</strong> fex<strong>of</strong>enadine hydrochlori<strong>de</strong> 180 mg alone and with alcohol, with hydroxyzine hydrochlori<strong>de</strong> 50 mg as a positive internal control, on aspects <strong>of</strong> cognitive and psychomotor function related to driving a car. Clin. Ther., 25(5), 1518-1538. 26. Rombaut, N.I.E., Hindmarch, I., 1994 - Psychometric aspects <strong>of</strong> antihistamines: a review, Hum. Psychopharmacol., 9, 157-169. 27. Roth, T., Roehrs, T., Koshorek, G., Sicklesteel, J., Zorick, F., 1987 - Sedative effects <strong>of</strong> antihistamines. J. Allergy Clin. Immunol., 80(1), 94-98. 28. Schwartz, J.-C., Arrang, J.-M., 2002 - Histamine. In: Davis K.L., Charney D., Coyle J.T., Nemer<strong>of</strong>f C. (eds.), Neuropsychopharmacology: the fifth generation <strong>of</strong> progress, American College <strong>of</strong> Neuropsychopharmacology, 179-190. 29. Shamsi, Z., Hindmarch, I., 2000 - Sedation and antihistamines: A review <strong>of</strong> inter-drug difference using proportional impairment ratios, Hum. Psychopharmacol. Clin. Exp., 15, 3-30. 30. Simons, F.E., Fraser, T.G., Reggin, J.D., Simons, K.J., 1996 - Comparison <strong>of</strong> the central nervous system effects produced by six H1-receptor antagonists. Clin. Exp. Allergy, 26(9), 1092-1097. 31. Simons, F.E.R., 1999 - Non-cardiac adverse effects <strong>of</strong> antihistamines (H1-receptor antagonists). Clin. Exp. Allergy, 29(S3), 125-132. 32. Slater, J.W., Zechnich, A.D., Haxby, D.G., 1999 - Second-generation antihistamines, a comparative review. Drugs, 57(1), 31-47. 33. Tagawa, M., Kano, M., Okamura, N., et al., 2001 - Neuroimaging <strong>of</strong> histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study <strong>of</strong> ebastine, a second-generation antihistamine, and chlorpheniramine, a classical antihistamine. Br. J. Clin. Pharmacol., 52(5), 501-509. 34. Tamai, I., Tsuji, A., 2000 - Transporter-mediated permeation <strong>of</strong> drugs across the bloodbrain barrier. J. Pharm. Sci., 89(11), 1371-1388. 102
35. Tashiro, M., Mochizuki, H., Iwabuchi, K., et al, 2002 - Roles <strong>of</strong> histamine in regulation <strong>of</strong> arousal and cognition: functional neuroimaging <strong>of</strong> histamine H1 receptors in human brain. Life Sci., 72(4-5), 409-414. 36. Timmerman, H., 2000 - Factors involved in the absence <strong>of</strong> sedative effects by the secondgeneration antihistamines. Allergy, 55(S60), 5-10. 37. Valk, P.J., Simons, R.M., Struyvenberg, P.A., Kruit, H., van Berge Henegouwen, M.T., 1997 - Effects <strong>of</strong> a single dose <strong>of</strong> loratadine on flying ability un<strong>de</strong>r conditions <strong>of</strong> simulated cabin pressure. Am. J. Rhinol., 11(1), 27-33. 38. Vuurman, E.F., van Veggel, L.M., Uiterwijk, M.M., et al, 1993 - Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann. Allergy, 71(2), 121-126. 39. Warren, R., Simpson, H., Hilchie, J., 1981 - Drugs <strong>de</strong>tected in fatally injured drivers in the province <strong>of</strong> Ontario. In: Goldberg L (ed.), Alcohol, Drugs and Traffic Safety, Volume 1. Stockholm: Almquist and Wiksell, 203-217. 40. Yanai, K., Okamura, N., Tagawa, M., Itoh, M., Watanabe, T., 1999 - New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin. Exp. Allergy, 29(S3), 29-36. 41. Yanai, K., Ryu, J.H., Watanabe, T., et al, 1995 - Histamine H1 receptor occupancy in human brains after single oral doses <strong>of</strong> histamine H1 antagonists measured by positron emission tomography. Br. J. Pharmacol., 116, 1649-1655. 42. Yokoyama, H., Iinuma, K., Yanai, K., et al, 1993 - Proconvulsant effect <strong>of</strong> ketotifen, a histamine H1-antagonist, confirmed by the use <strong>of</strong> d-chlorpheniramine with monitoring electroencephalography, Methods Find. Exp. Clin. Pharmacol., 15, 183-188. 103
- Page 1 and 2:
Vol. 3, Nr. 3, 4 2003 JURNALUL ROM
- Page 3 and 4:
A R P F Romanian Journal of Psychop
- Page 5 and 6:
EVALUATION DES MEDICAMENTS DANS LE
- Page 7 and 8:
Enfin dans le cadre de l’épisode
- Page 9 and 10:
cas ou un tel médicament serait é
- Page 11 and 12:
ECHELLE C.G.I. (Clinical Global Imp
- Page 13 and 14:
12. Frank E, Kupfer DJ, Gerebtzoff
- Page 15 and 16:
Pour définir les critères d'inclu
- Page 17 and 18:
ESTE JUSTIFICATĂ INTERVENŢIA TERA
- Page 19 and 20:
pacienţii care au avut o durată m
- Page 21 and 22:
7. Loebel A.D., Lieberman J.A, Alvi
- Page 23 and 24:
determină creşterea concentraţie
- Page 25 and 26:
special de disfuncţia noradrenergi
- Page 27 and 28:
PSIHOFARMACOLOGIA CLINICĂ A TERAPI
- Page 29 and 30:
apare la un interval de timp bine d
- Page 31 and 32:
c) Studiul Zürich (Jules Angst, 19
- Page 33 and 34:
mai cu seamă a terapiilor combinat
- Page 35 and 36:
Descoperirea în ordine cronologic
- Page 37 and 38:
Succesiunea de etape istorico-crono
- Page 39 and 40:
prurigo, etc) interpretate diagnost
- Page 41 and 42:
Antidepresivele de generaţia a pat
- Page 43 and 44:
Bibliografie 1. Frank E, Prien RF,
- Page 45 and 46:
TERAPIA BIOLOGICĂ A DEPRESIILOR I.
- Page 47 and 48:
Indicaţia primară a Carbamazepine
- Page 49 and 50:
3. Currier, B. M., Murray, G. & Wel
- Page 51 and 52:
În cursul tratamentului pot interv
- Page 53 and 54:
Aplicând scala MADRS la pacienţii
- Page 55 and 56: Proprietăţile antihistaminice H1
- Page 57 and 58: Utilizarea antihistaminicelor H1 ne
- Page 59 and 60: s-a dovedit într-un studiu multice
- Page 61 and 62: În plus, depresia este corelată c
- Page 63 and 64: 21. Juhlin, L., 1981 - Recurrent ur
- Page 65 and 66: DEPRESIA ŞI EPILEPSIA G. Bădescu,
- Page 67 and 68: Rolul GABA în depresie - un defici
- Page 69 and 70: menţionează 25 % simptome psihiat
- Page 71 and 72: 10. Kanner, A.M., Palac, S., 2000 -
- Page 73 and 74: De la descoperirea primului antidep
- Page 75 and 76: Tratamentul de lungă durată cu am
- Page 77 and 78: Tachikininele produc fenomenul de
- Page 79 and 80: Hiperactivitatea locomotorie şi mo
- Page 81 and 82: Efectele secundare în sfera sexual
- Page 83 and 84: 15. Saria A., 1999 - The tachykinin
- Page 85 and 86: Termenul de neuropsihoendocrinologi
- Page 87 and 88: Atât pacienţii depresivi cât şi
- Page 89 and 90: Bibliografie selectivă 1. Agid, O.
- Page 91 and 92: TRATAMENTUL CU SERTRALINĂ ÎN TULB
- Page 93 and 94: În cel de-al doilea lot, a existat
- Page 95 and 96: EFECTUL SEDATIV ŞI ALTERAREA PERFO
- Page 97 and 98: La doze terapeutice, clorfeniramina
- Page 99 and 100: arierei hematoencefalice de către
- Page 101 and 102: decât pentru loratadină, fără d
- Page 103 and 104: viteză de 95 km/h, reprezintă o c
- Page 105: 6. Hindmarch, I., Shamsi, Z., 1999
- Page 109 and 110: În insuficienţa hepatică cronic
- Page 111 and 112: În hiperamoniemia moderată cronic
- Page 113 and 114: c. GABA (acid gamma aminobutiric) e
- Page 115 and 116: Iată deci cum factori diferiţi, c
- Page 117 and 118: Perspectiva psihosocială Buss - 19
- Page 119 and 120: În sindromul Kluver-Bucy (ablaţia
- Page 121 and 122: Bibliografie selectivă 1. Allen, T
- Page 123 and 124: International Journal for Postgradu
- Page 125 and 126: familia pacientului, formularea pla
- Page 127 and 128: Participarea familiei trebuie să i
- Page 129 and 130: VI. Antipsihoticele convenţionale:
- Page 131 and 132: Chiar dacă toate aceste medicament
- Page 133 and 134: ezistenţi la tratament (19, 35, 36
- Page 135 and 136: În studiile controlate în alte tu
- Page 137 and 138: Ib. Iloperidona Iloperidona este un
- Page 139 and 140: 9. American Psychiatric Association
- Page 141 and 142: 42. Casey DE. Side effects profiles
- Page 143 and 144: 67. von Fischer-Cornelssen K, Ferne
- Page 145 and 146: 93. Klieser E, Lehmann E, Kinzler E
- Page 147 and 148: 121. Beasley Jr CM, Hamilton SH, Cr
- Page 149 and 150: schizophrenia presenting psychotic
- Page 151 and 152: 168. Segal J, Berk M, Brook S. Risp
- Page 153 and 154: 192. Hale AS. A review of the safet
- Page 155 and 156: 215. Hori M, Suzuki M, Shiraishu H,
- Page 157 and 158:
240. Honigfeld G, Patin J. A two-ye
- Page 159 and 160:
266. Barnas C, Stuppaeck CH, Miller
- Page 161 and 162:
I. Strategii de comunicare 1. COMUN
- Page 163 and 164:
2.2 Recomandări Profesioniştii as
- Page 165 and 166:
4.2 Recomandări � Cel puţin în
- Page 167 and 168:
� Trebuie elaborate şi larg dist
- Page 169 and 170:
schizofrenie nu au „personalită
- Page 171 and 172:
instituţionalizări (18). Cu toate
- Page 173 and 174:
9. Revicki DA. Pharmacoeconomic eva
- Page 175:
Instructions to authors The text mu